Voloridge Investment Management
DAWN

Voloridge Investment Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Voloridge Investment Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-146,041
Closed -$3.14M – 1404
2022
Q4 		$3.14M Sell
146,041
-61,224
-30% -$1.26M 0.02% 831
2022
Q3 		$4.15M Buy
+207,265
New +$4.41M 0.02% 708

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management's DAWN Position: Q1 2023 in Review

Voloridge Investment Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2023, closing a stake of 146,041 shares — an estimated $3.14M sold.

Voloridge Investment Management first reported a position in DAWN in Q3 2022 and held it in 2 quarters. The position peaked at $4.15M in Q3 2022. 126 funds tracked by Wall St. Rank hold DAWN as of Q1 2023.

  • Voloridge Investment Management reported no remaining Day One Biopharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Voloridge Investment Management sold 146,041 Day One Biopharmaceuticals shares in Q1 2023, an estimated $3.14M.
  • Voloridge Investment Management first reported a position in Day One Biopharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Voloridge Investment Management's Day One Biopharmaceuticals position peaked at $4.15M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2023.

Based on Voloridge Investment Management's 13F filing for Q1 2023, filed 15 May 2023.